Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0001456

Nitrendipine for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nitrendipine, 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H20N2O6
CAS Number:
39562-70-4
Molecular Weight:
360.36
MDL number:
MFCD00082255
UNSPSC Code:
41116107
PubChem Substance ID:
329831432
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nitrendipine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC

InChI

1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3

InChI key

PVHUJELLJLJGLN-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nitrendipine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Mancini et al.
Journal of cardiovascular pharmacology, 18 Suppl 1, S30-S33 (1991-01-01)
There is evidence that hypertensive patients frequently have other metabolic disorders, such as hyperlipidemia and diabetes mellitus. It is also known that the reduction in high blood pressure alone, disregarding the other cardiovascular risk factors, is unable to reduce mortality
R L Byyny
Journal of cardiovascular pharmacology, 14 Suppl 10, S27-S32 (1989-01-01)
Throughout the developed world, populations are growing older. Blood pressure, especially systolic blood pressure, increases with aging, and this increase leads to increased risks of cardiovascular morbidity and mortality. Clinical trials demonstrate that treatment of hypertension in the elderly reduces
M Eichelbaum et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S6-10 (1988-01-01)
Nitrendipine [3-ethyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate] is a calcium antagonist with a dihydropyridine structure that has a great structural resemblance to nifedipine. Instead of a methyl group in position 3, it has an ethyl group and the NO2 group is in the meta
S Kazda et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S1-S5 (1988-01-01)
The mechanism of the antihypertensive effect of nitrendipine is believed to be vasodilation, resulting in a reduction of the total peripheral resistance. However, in contrast to other arteriolar vasodilators, nitrendipine exerts natriuretic and diuretic effects that are more pronounced in
B N Trost et al.
Journal of cardiovascular pharmacology, 6 Suppl 7, S986-S995 (1984-01-01)
Some calcium antagonists, including nitrendipine, were noted to cause a dose-dependent and reversible inhibition of insulin release in certain animal models. Therefore, it is important to know the effects of clinical treatment with calcium antagonists in nondiabetic or diabetic man.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service